Document:

EXHIBIT 10.3
                                LICENSE AGREEMENT

      This License Agreement ("Agreement"), dated February 3, 2000, and
      effective as of the EFFECTIVE DATE (defined below), is entered into at
      Houston, Texas by and between CytoGenix, Inc. a Nevada corporation having
      an office at 9881 South Wilcrest Street, Houston, Texas 77099 (CYGX), and
      PharmaGenix, LLC, a Nevada limited liability company having an office at
      9883 South Wilcrest Street, Houston Texas 77099 (LICENSEE). CYGX and
      LICENSEE are also referred to individually as "PARTY" and collectively as
      "PARTIES".

      RECITALS

            1. LICENSEE desires to obtain an exclusive license to use certain
      technology in the FIELD OF USE defined in Paragraph 1.07 under certain
      patent(s), patent application(s), trademark(s), copyright(s), know-how,
      show-how and trade secret(s) that is/are owned or developed by CYGX or to
      which CYGX has license rights; and

            2. CYGX is willing to grant to LICENSEE a license to use such CYGX
      TECHNOLOGY on LICENSEE's behalf in the Field OF USE on the conditions set
      forth in this Agreement.

            NOW THEREFORE, the PARTIES agree as follows:

      ARTICLE I - DEFINITIONS

      1.01 AFFILIATE(s) of any specified PERSON or PARTY means any other which,
      directly or indirectly, is in control of, is controlled by or is under
      common control with such specified PERSON. For purposes of this
      definition, "control of a PERSON" means the power, directly or indirectly,
      to direct or cause the direction of the management and policies of such
      PERSON whether by contract or otherwise; and the terms "controlling" and
      "controlled" have meanings correlative to the foregoing.

      1.02 BACKGROUND INVENTIONS means all inventions that are conceived,
      reduced to practice or both, together with associated patents and patent
      applications that are owned by either PARTY or under which a PARTY
      otherwise has the right to grant licenses without accounting to any third
      PARTY or to the other PARTY, where the inventions claimed can be practiced
      without infringing any claim of PATENTS.

      1.03 CONFIDENTIAL INFORMATION means all information about CYGX TECHNOLOGY,
      as defined hereinbelow, information that CYGX has the right to license,
      but which is neither made freely available by CYGX to its customers nor
      published nor otherwise made available to the public through sources
      entitled to disclose

                                       1
<PAGE>
      the same, relating to the manufacture, use and sale of Product or the
      preparation and sale of a compound that contains Product or the practice
      of Process. Confidential Information includes such information, whether or
      not confirmed in writing by CYGX as being confidential, as is neither made
      freely available by CYGX to its customers nor published nor otherwise made
      available to the public through sources entitled to disclose the same.

      1.04 CYGX IMPROVEMENTS means any modification or Process, Product or both
      that is made by or on behalf of CYGX during the term of this Agreement,
      provided such modification, if unlicensed, would infringe one or more
      claims of Patents. CYGX IMPROVEMENTS shall include know-how related to
      and/or developments in respect of components, materials, or processes
      useful in practicing the inventions of Patents.

      1.05 CYGX TECHNOLOGY means Patents, Patents pending, Copyrights,
      Trademarks, Tradenames, KNOW-HOW, CYGX IMPROVEMENTS and/or proprietary
      information developed and or held by CYGX as may be applicable to
      commercialization opportunities in the FIELD OF USE.

      1.06 EFFECTIVE DATE means the date this Agreement has been executed by
      authorized representatives of CYGX and LICENSEE and any necessary
      governmental approvals and, where appropriate, registrations have been
      obtained.

      1.07 FIELD OF USE used in this Agreement means the employment of uses and
      /or methods described in any issued U.S. Patents, Patent Applications,
      Continuations, Continuations in Part or Divisionals of which CYGX is
      inventor, assignee, or licensee as well as to CYGX TECHNOLOGY and
      CONFIDENTIAL INFORMATION for the purpose of producing PHARMACOGENOMIC
      SUBSTANCES.

      1.08 FORCE MAJEURE, as used in this Agreement, means war or insurrection,
      fire, flood, strike, labor trouble, work stoppage, embargo, accident,
      riot, act of governmental authority, act of God, or contingency beyond the
      reasonable control of the PARTIES which prevent performance of obligations
      under this Agreement.

      1.09 KNOW HOW means, as of the EFFECTIVE DATE, all business and technical
      information relating to the use of single stranded nucleic acids in
      composing, prescribing or utilizing PHARMACOGENOMICS, as well as all show
      how including business and technical information considered a trade secret
      as defined hereinbelow, and that exists as of the EFFECTIVE DATE and that
      CYGX is free to disclose. Such information is more fully described in
      Annex A of this Agreement.

      1.10 LICENSEE IMPROVEMENTS means all discoveries and/or inventions
      (whether patented or not) made by LICENSEE during the term of this
      Agreement that constitute a modification of Process and/or Product and
      that would, if practiced, constitute an infringement of one or more of
      CYGX's Patents.

      1.11 NET SELLING PRICE means, for purposes of computing royalties under
      this

                                       2
<PAGE>
      Agreement, LICENSEE's invoice price for Product(s), f.o.b. factory, on an
      arm's length trade basis, after deduction of regular trade and quantity
      discounts, but before deduction of any other items, including, but not
      limited to, freight allowances, cash discounts, and agents' commissions.

      1.12 PATENTS means all patents issued as of the Effective Date and all
      patents issuing in the future on patent applications pending as of the
      Effective Date of this Agreement, as well as patents issuing from later
      filed continuations, continuations in part, substitutions, or divisionals
      thereof, and any reissues thereof, that CYGX either owns or, as a
      LICENSEE, has the right to sublicense and that cover applications in the
      FIELD OF USE. The listing of patents and patent applications provided in
      Annex B of this Agreement illustrates, but may not include all, CYGX
      patent rights.

      1.13 PERSON means any individual, corporation, partnership, joint venture,
      association, joint-stock company, trust, unincorporated organization,
      government or any agency or political subdivision thereof or any other
      entity.

      1.14 PHARMACOGENOMICS means the science related to the identification and
      elucidation of genetic variations that correlate with an the individual's
      response and reaction to specific drugs and using specific nucleotide
      sequences to alter expression of selected genes to achieve a therapeutic
      result.

      1.15 PRODUCT(s) shall mean only therapeutic substances composed or
      compounded using KNOW HOW or PATENTS.

      1.16 SUBLICENSEE shall mean a PERSON acquiring rights to use some or all
      CYGX TECHNOLOGY in accordance with agreement(s) with LICENSEE and approved
      in writing in advance of execution by CYGX.

      1.17 TERRITORY means the world.

      1.18 THIRD PARTY means a Person who is not CYGX, LICENSEE or an Affiliate
      of CYGX or LICENSEE.

      1.19 TRADEMARKS means CYGX's registered tradenames, service marks and/or
      trademarks that relate to Products or to Process, whichever is
      appropriate.

      1.20 Words and phrases used in this Agreement which are not otherwise
      defined shall be interpreted in accordance with the common usage for such
      term in the United States of America. Technical terms unless otherwise
      defined shall be interpreted consistent with their common usage in the
      Field. Words in the singular include the plural and vice versa, unless
      expressly or implicitly limited.

                                       3
<PAGE>
ARTICLE II - GRANTS

      2.01 CYGX grants LICENSEE an exclusive, royalty-bearing, non-assignable
      (without CYGX's prior written permission), license TO CYGX TECHNOLOGY with
      the right to sublicense under terms of Article XIII hereinbelow in the
      TERRITORY.

      2.02 Neither PARTY grants the other PARTY any right or license under any
      of its Background Inventions.

ARTICLE III - CONSIDERATION

      3.01 LICENSEE agrees to pay to CYGX the sum of Fifty Thousand Dollars
      ($50,000) as an initial fee. The initial fee shall not be deemed an
      advance payment of minimum or earned royalty.

      3.02 In consideration for the rights granted under this Agreement,
      LICENSEE agrees to pay CYGX the sum specified in Paragraph 3.01 above and
      a running royalty at a rate of Nine percent (9%) of the Net Selling Price
      of Products, said running royalty to be paid within Thirty (30) days after
      each anniversary of the Effective Date during the term of this Agreement.

      3.03 LICENSEE shall pay CYGX a minimum annual royalty according to the
      following schedule:

          $5,000      at the second anniversary of the EFFECTIVE DATE;
          $10,000     at the third anniversary of the EFFECTIVE DATE;
          $15,000     at the fourth anniversary of the EFFECTIVE DATE; and
          $15,000     at following anniversaries thereafter for the term of the
                      License.

      Any difference between earned royalties for a calendar year hereunder and
      the specified minimum is to be paid with the accounting report for each
      calendar fourth quarter.

      3.04 All payments due to CYGX are net amounts. In the event any payment
      due under this Agreement is subject to or becomes subject to any tax or
      other deduction payable by LICENSEE, such tax or deduction shall be paid
      by LICENSEE, so that the payment to CYGX shall be in full and free of all
      liability for such tax or other deduction.

      3.05 All earned royalties paid pursuant to the provisions of Paragraph
      3.02 for any year shall be applicable in reduction or discharge, as the
      case may be, of the minimum royalty obligations pertaining to such year.
      In the event of termination within any year hereunder the foregoing
      minimum royalty obligations shall be prorated.

      3.06 LICENSEE undertakes to make all payments due under provisions of this
      Agreement in United States dollars (US$) provided that such payment is
      consistent with

                                       4
<PAGE>
      existing legal provisions. In the case of running royalties, CYGX shall
      have the option to take such payments in the currency(ies) of the
      countries in which the licenses granted herein are being practiced, the
      royalty rate being converted to the currency(s) of such countries at that
      rate of exchange running on the day said payment is made to CYGX. LICENSEE
      shall pay all amounts owed to CYGX by wire transfer in immediately
      available funds unless otherwise agreed upon in writing between the
      PARTIES.

      3.07 LICENSEE shall pay CYGX interest on any money which is 30 days or
      more past due at a rate of three percent (3%) above the then current prime
      rate as announced from time to time by Citibank, N.A., New York, New York,
      or the maximum rate allowable by law, whichever is lower.

      3.08 In the event CYGX terminates the licenses granted under this
      Agreement for non-payment of royalties by LICENSEE, in accordance with
      Paragraph 20.03 below, all amounts then owing by LICENSEE shall
      immediately become due and payable.

      3.09 No royalty shall be paid for PRODUCT produced in any country where
      all dominating patent claims within PATENTS have expired and/or been held
      invalid by a court of competent jurisdiction.

      3.10 For the purpose of determining the dates when earned royalties accrue
      hereunder, Product(s) shall be considered to be sold when such Product(s)
      is/are billed out to a third PARTY or, if not so billed out, then when
      delivered or paid for if paid for before delivery. No payments shall be
      due on such Product(s) sold or delivered as replacements for defective
      Product(s) or on Product(s) that are returned by purchasers for credit or
      on Product(s) as to which full credit is granted customers due to defect
      in the Product(s) or on Product(s) that are lost or damaged in transit for
      which seller is not reimbursed.

      3.11 LICENSEE shall pay CYGX for any technical assistance provided under
      Article XV as specified in that Article.

      3.12 The royalties specified in Paragraph 3.02 above shall be due
      throughout the life of the Agreement.

ARTICLE IV - RECORDS AND REPORTS

      4.01 LICENSEE shall keep accurate and sufficient records to determine
      amounts owed to CYGX under this Agreement. LICENSEE shall make a written
      report detailing the basis for any computations to CYGX at the address
      specified in Article XX, within thirty (30) days following each calendar
      quarter. LICENSEE shall transmit payment for the royalty shown to be due
      with the report for the fourth quarter of each calendar year.

      4.02 Records necessary for the computation of amounts payable by LICENSEE
      under this Agreement shall be maintained by LICENSEE for a period of five
      (5) years following

                                       5
<PAGE>
      each accounting report due to include the last accounting report due upon
      termination of this Agreement for any reason. Such records shall be open
      to inspection by an auditor selected by CYGX to which LICENSEE has no
      reasonable objection during regular business hours of LICENSEE. Such
      records shall only be used by CYGX or its agents to determine the accuracy
      of the royalties paid and reports submitted. CYGX shall bear the expenses
      of the auditor it selects, except LICENSEE shall reimburse CYGX for such
      expenses in the event the total underpayment of royalties identified
      during the audit exceeds the cost of the audit.

ARTICLE V - CONFIDENTIALITY

      5.01 LICENSEE agrees to maintain Confidential Information in confidence
      using the same degree of care as LICENSEE takes to safeguard its own
      proprietary information of the same general nature, but in no event shall
      LICENSEE use less than a reasonable degree of care, and to refrain from
      disclosing Confidential Information to others during the term of this
      Agreement and for a period of Three _____ (3) years after termination of
      this Agreement

      5.02 LICENSEE agrees that it will not use, except for purposes expressly
      licensed under this Agreement, any Confidential Information obtained
      directly or indirectly from CYGX in the course of communications and
      contacts related to this Agreement. This obligation extends to all
      information that may be obtained or derived incidentally, such as by
      visits to plants of CYGX or its Affiliates and from discussions about
      peripheral technologies or business information. All such types of
      information are included within the term CONFIDENTIAL INFORMATION.

      5.03 LICENSEE shall limit disclosure of Confidential Information to those
      of its employees who have a need to know the same and shall inform such
      employees who receive Confidential Information of its sensitive and
      confidential nature and of LICENSEE's obligations under this Agreement.

      5.04 LICENSEE may, with CYGX's prior written permission, which shall not
      unreasonably be withheld, disclose Confidential Information pertaining to
      the Product(s), Process or both to other Persons in the regular course of
      where necessary, provided such other Persons agree in writing to abide by
      obligations of confidentiality no less stringent than those contained in
      this Agreement. CYGX retains the right not to allow certain information to
      be disclosed to a Third PARTY or to approve in advance such disclosure in
      writing, even if such PARTY agrees to execute a similar confidentiality
      agreement.

      5.05 The obligations of confidentiality shall not apply to any information
      which:

            (A) was known to LICENSEE prior to the receipt of such information
      from CYGX, as evidenced by written records or other reliable evidence, and
      such information was not directly or indirectly derived from CYGX or CYGX
      Affiliates;

                                       6
<PAGE>
            (B)   is or becomes known to the general  public  through no fault
      of LICENSEE;

            (C) is received by the LICENSEE without restriction on its
      disclosure or in good faith from a third PARTY purporting to have the
      right to transmit the same;

            (D) is independently developed by employees of LICENSEE who have had
      no access to Confidential Information; and/or

            (E) is required to be disclosed to governmental authorities or
      courts as a result of operation of law, regulation, or court order,
      provided however, immediate written notice of any such request by
      governmental authorities or courts must be provided to CYGX, all
      reasonable steps must be taken by LICENSEE to restrict further disclosure
      of the affected information by said authorities or court and information
      so disclosed shall not be otherwise removed from these secrecy
      obligations; provided, however, that no use or disclosure apart from
      licensed purposes may be made as to any item of protected information
      (information subject to an obligation of confidence) in reliance on any of
      exceptions (A) -(E) unless such use or disclosure is preceded by ten (10)
      business days prior written notice from the receiving PARTY to the
      original disclosing PARTY, which notice explains the nature and scope of
      the intended use or disclosure and includes a detailed recitation of facts
      that give rise to one or more of the applicable exceptions (A) -(E).

      5.06 Specific information shall not be deemed to fall within any of the
      exceptions enumerated in Paragraph 5.05 above merely because such
      information is embraced by more general information in the public domain.

ARTICLE VI - CYGX REPRESENTATIONS, WARRANTIES AND INDEMNIFICATIONS

      6.01 CYGX warrants that it owns and has the necessary authority to grant
      the licenses specified in Article II. 6.02 CYGX shall not be liable for
      any special, incidental, or consequential damages, including, but not
      limited to, personal injury, property damage or shutdown or non-operation
      of any facility, however caused or under any theory of liability, whether
      based in contract, tort (including negligence), strict liability, patent
      infringement or otherwise and regardless of whether either PARTY has been
      advised of the possibility of such damage.

      6.03 CYGX MAKES NO REPRESENTATION OR WARRANTY OF MERCHANTABILITY OR
      FITNESS FOR A PARTICULAR PURPOSE, NOR IS THERE ANY OTHER EXPRESSED OR
      IMPLIED WARRANTIES EXCEPT THOSE EXPRESSLY STATED IN THIS ARTICLE.
      LICENSEES' REMEDIES WITH RESPECT TO CYGX'S REPRESENTATIONS AND WARRANTIES
      ARE LIMITED TO THOSE EXPRESSLY STATED IN THIS AGREEMENT.

                                       7
<PAGE>
      6.04 CYGX makes no warranties with respect to freedom from alleged
      infringement of third PARTY patents or freedom from third PARTY
      infringers, and CYGX is not under any obligation to hold LICENSEE harmless
      against such alleged infringement of third PARTY patents nor to enforce
      its patent properties against alleged infringers.

      6.05 LICENSEE is solely responsible for its activities carried out under
      the license granted hereunder. Save for the representation made in
      Paragraph 6.01 above, CYGX makes no representations, extends no warranties
      of any kind, either express or implied, and assumes no responsibilities
      whatsoever with respect to the practice by LICENSEE, its customers, or
      leasees of, CYGX's Know-How, Patent(s) or both, and LICENSEE agrees to
      hold CYGX harmless from and assume all risk, liability, or lawsuits
      arising out of, or in the course of, such practice.

      6.06 LICENSEE understands and agrees that CYGX does not warrant the
      validity of the patents or the patentability of the patent applications
      licensed herein. CYGX assumes no liability if, as a result of LICENSEE's
      use of the patented process licensed hereunder, LICENSEE should be sued
      for alleged infringement of any patent not owned or controlled by CYGX,
      but CYGX will, to the extent only of the royalties theretofore paid
      hereunder, reimburse LICENSEE for any sums assessed against and paid by
      LICENSEE as a result of any judgment rendered in any such suit.

      6.07 CYGX makes no representation or warranty as to the commercial utility
      of technology covered by IP Rights.

      6.08 There is no implied license to LICENSEE under any patent or
      application for patent not specified herein and there are no
      understandings, written or oral, of any nature whatsoever concerning this
      Agreement or the license(s) granted herein not covered by this written
      Agreement.

ARTICLE VII - LICENSEE REPRESENTATIONS, WARRANTIES AND INDEMNIFICATIONS

      7.01 LICENSEE warrants to CYGX that LICENSEE has the authority to enter
      into this Agreement. LICENSEE represents and warrants that it has obtained
      any and all governmental approvals required for the obligations under this
      Agreement.

      7.02 LICENSEE represents and warrants to CYGX that LICENSEE has, either
      in-house or at its disposal, the expertise necessary to use the Technology
      in a safe and effective manner. LICENSEE acknowledges that (a) CYGX has no
      control over, or responsibility for, the manner in which LICENSEE utilized
      the Technology under the terms of this Agreement, and (b) LICENSEE
      utilizes the Technology at its own risk.

                                       8
<PAGE>
      7.03 LICENSEE represents and warrants that LICENSEE shall not claim
      against CYGX or any CYGX employee, agent, director or Affiliate any of the
      claims for damages referenced in Paragraph 6.02 and shall obligate any
      LICENSEE Affiliate, agent, employee, contractor, insurer or SUBLICENSEE,
      if any, not to bring such damage claims against CYGX

      7.04 LICENSEE shall defend, indemnify and hold harmless CYGX, its
      successors, assigns, officers, directors, employees and agents from any
      and all claims, causes of action, losses, liabilities and expenses
      including, but not limited to, reasonable attorneys' fees) to third
      PARTIES (including LICENSEEs' employees [AND ANY SUBLICENSEE] arising out
      of any breach of this Agreement by LICENSEE or personal injury, death,
      environmental damage or property damage or any defects in design,
      materials or workmanship of any kind.

      7.05 It is understood that CYGX will not assume any responsibility or
      liability for the personal safety of any representatives from LICENSEE who
      might be present at the CYGX offices or laboratories for the purpose of
      observing or evaluating PROCESSES, PRODUCTS or other information or
      activities related to the subject matter of this Agreement, and LICENSEE
      hereby releases CYGX from any claim for injury, death, or damage, which
      may arise from such presence.

ARTICLE VIII - LICENSEE IMPROVEMENTS

      8.01 When LICENSEE has determined to grant an exclusive license under a
      LICENSEE Improvement, LICENSEE will first offer the license to CYGX and,
      in the event CYGX fails to accept the offer within Sixty (60) days,
      LICENSEE will be free to offer the license to any third PARTY on terms no
      more favorable to such third PARTY than those offered to CYGX. When
      LICENSEE has determined to grant nonexclusive licenses under such LICENSEE
      Improvement, LICENSEE will notify CYGX, and at any time upon CYGX's
      request, will grant to CYGX a nonexclusive license to make, use and sell
      the claimed invention(s)of such LICENSEE Improvement. Such nonexclusive
      licenses will be on terms and conditions no less favorable than have been,
      or are thereafter, offered to any third PARTY; and in the event no
      previous licenses have been granted, the licenses to CYGX will be for a
      reasonable royalty.

      8.02 Should any patentable development(s) relating to CYGX's proprietary
      information and samples transmitted to LICENSEE be made by one or more
      employees of LICENSEE during tests carried out hereunder or as a direct
      consequence thereof, and should any patents be obtained by LICENSEE
      covering such LICENSEE developments, LICENSEE shall grant CYGX a
      royalty-free, nonexclusive license throughout the world to practice the
      claimed invention(s) with a right to extend to CYGX's customers a right to
      practice the same.

                                       9
<PAGE>
ARTICLE IX - ENFORCEMENT OF  LICENSEE PATENT RIGHTS

      9.01 If CYGX holds a license to LICENSEE Improvements in accordance with
      Paragraph 8.01 above and gives written notice to LICENSEE that a third
      PARTY is employing such LICENSEE Improvements without the right of a
      license from LICENSEE, LICENSEE shall proceed by appropriate means to
      restrain such infringement. If LICENSEE fails to restrain such
      infringement within Sixty (60) days after receiving such notice, CYGX
      shall have the right to discontinue royalty payments due LICENSEE under
      Paragraph 8.01 above until such time that said third PARTY infringement
      ceases.

ARTICLE X - ENFORCEMENT OF LICENSED PATENTS

      10.01 LICENSEE shall notify CYGX in writing of any conflicting uses of, or
      any applications or registrations for, the technology covered by the
      grants made in Article II, or of any acts of infringement or acts of
      unfair competition involving CYGX's Patents or Know-How, promptly after
      such matters are brought to LICENSEE's attention or it has knowledge
      thereof.

      10.02 In the event that any third PARTY shall infringe any claims of
      CYGX's Patents, LICENSEE may, at its option, send written notice thereof
      to CYGX requesting that CYGX take action to abate such infringement or
      bring suit against such infringer. Beginning six (6) months from the date
      of receipt of such notice by CYGX, LICENSEE may suspend further royalty
      payments due under any such infringed claims unless and until CYGX shall
      abate such infringement or bring such suit. In the event infringement is
      abated or suit is filed, royalty payments shall be resumed and suspended
      royalty payments shall become due. CYGX shall not be required to expend
      more then Fifty (50) percent of any royalties received from LICENSEE under
      this Agreement for such infringement action or to prosecute more than one
      such infringement suit at a time in any country. If any claim of any
      patent within CYGX's Patents shall be declared invalid by a judicial
      decision which shall become final, then LICENSEE shall thereafter be under
      no obligation to pay royalties for operation under such claim unless such
      operation is dominated by one or more claims of CYGX's Patents not
      declared invalid.

      10.03 CYGX and LICENSEE mutually shall have the right to institute action
      for infringement of any CYGX's Patents, it being agreed that in any such
      action that both PARTIES mutually agree to institute, the action shall be
      instituted in the names of both such PARTIES and that both such PARTIES
      shall contribute equally to the expense of any such action and shall
      participate equally in the recoveries, if any, whether by judgment, award,
      decree or settlement. It is further agreed that CYGX shall exercise
      control over such action, provided, however, that LICENSEE may be
      represented by counsel of its selection and at its expense. In the event
      such PARTIES do not mutually agree to institute such action, either such
      PARTY hereto may institute such action and join the other as a PARTY
      complainant in such action; the PARTY so instituting the

                                       10
<PAGE>
      action shall defray the entire expenses of such action and shall be
      entitled to retain the entire amount of the recoveries, if any, by way of
      judgment, award, decree or settlement resulting therefrom.

      10.04 In the event that, during that portion of the duration of this
      Agreement that LICENSEE has an exclusive license under CYGX's Patents,
      LICENSEE can prove to CYGX's satisfaction that a third PARTY is infringing
      any claim(s) in CYGX's Patents and thereby materially and adversely
      affecting LICENSEE's sublicensing of CYGX's Patents, LICENSEE may request
      CYGX in writing to take reasonable steps to assist LICENSEE to license
      such third PARTY under at least the infringed claim(s) of CYGX's Patents
      and, thereafter, if said infringer refuses such a license under terms no
      less favorable than those terms of other sublicenses granted under CYGX's
      Patents, to otherwise stop such infringement. Notification of such
      infringement to CYGX shall include the name of the infringer and all
      information LICENSEE possesses to substantiate the alleged infringement.
      If within six (6) months after receiving notice of infringement, CYGX does
      not take such reasonable steps to assist LICENSEE to license such third
      PARTY or otherwise stop the alleged infringement, LICENSEE may either: (a)
      pay into an interest bearing escrow account that portion of the payments
      due CYGX equal to the royalties which, if licensed, would be payable by
      said third PARTY infringer from the date CYGX receives such notice until
      such third PARTY has been licensed under the infringed claim(s) of CYGX's
      Patents or infringement has been otherwise stopped, at which time LICENSEE
      shall resume full payments to CYGX and pay CYGX all monies accrued in the
      escrow account; or (b) file an appropriate action for infringement of the
      infringed claim(s) in CYGX's name if necessary. In any event, if an action
      for infringement of any claim(s) in CYGX's Patents is filed, CYGX shall,
      with respect to CYGX and LICENSEE, have the right to control such
      litigation. Furthermore, it is agreed that CYGX's total financial
      responsibility in pursuing any infringement action under this Article X
      shall be limited to actions in which CYGX is a voluntary PARTY and in such
      actions to a total composite sum not exceeding fifty (50) percent of the
      payments actually paid to CYGX by LICENSEE for practice by SUBLICENSEEs
      under the infringed claim(s). In the event that CYGX prevails in any
      infringement action where CYGX is a voluntary PARTY, CYGX's expenditures
      for such action shall be reimbursed from any damages and/or costs awarded
      by the court before division of such amount between CYGX and LICENSEE. In
      any infringement action filed hereunder by LICENSEE, where CYGX is an
      involuntary PARTY, LICENSEE shall promptly reimburse CYGX for all expenses
      CYGX incurs as a result of such infringement action. In the event that
      LICENSEE prevails in any infringement action filed hereunder by LICENSEE,
      where CYGX is an involuntary PARTY,. LICENSEE's expenditures for such
      action shall be reimbursed from any damages and/or costs awarded by the
      court before division of such amount between LICENSEE and CYGX.

ARTICLE XI - HOLD HARMLESS

      11.01 LICENSEE acknowledges it is fully aware of the hazards associated
      with the

                                       11
<PAGE>
      Product, Process or both and undertakes to see that all possible methods
      and equipment are utilized to reduce the risks of property damage and
      personal injury from the use of the Process, handling of the Product or
      both, including instructing all employees or agents who may work with, or
      may be in any other way exposed to, the Process, the Product or both, of
      such hazards. In part consideration of the licenses granted in Article II
      of this Agreement, LICENSEE agrees to indemnify and hold harmless CYGX,
      its successors and assigns and their officers, employees and agents from
      any and all claims, causes of actions or losses of any sort for personal
      injury, including death, or property damage incurred by any person and/or
      LICENSEE arising out of LICENSEE's practice of licenses granted by this
      Agreement under any combination of Know-How, Confidential Information and
      Patents.

      11.02 In the event any suit for damages is brought against CYGX by any
      third PARTY, based on LICENSEE's use of the CONFIDENTIAL INFORMATION and
      CYGX TECHNOLOGY disclosed to LICENSEE under this Agreement, LICENSEE
      agrees to legally defend CYGX from any allegations under any such suit,
      and to hold CYGX harmless from any damages which might be awarded to said
      third PARTY, unless such damages are the result of gross negligence by
      CYGX, its agents or employees.

      11.03 LICENSEE shall carry liability insurance with insurance carriers
      acceptable to CYGX with limits of not less than One Million Dollars
      ($1,000,000) per person and One Million Dollars ($1,000,000) per
      occurrence, to include CYGX as a named insured in such insurance to the
      extent of its interest arising out of the indemnity and hold harmless
      provisions contained in this Article XI, and shall provide CYGX with a
      certification by the carrier of such insurance coverage along with a
      proviso that the insurance carrier shall provide at least Sixty (60) days
      written notice to CYGX prior to termination of such coverage. This
      Agreement shall automatically terminate upon termination of such insurance
      coverage.

      11.04 CYGX will not be liable to the LICENSEE in contract, in tort
      (including CYGX's negligence), under any warranty, or otherwise, for any
      special, incidental, indirect, or consequential damage or losses arising
      out of the performance of this Agreement and/or the practice of the CYGX
      Know-How and/or CYGX Patent Rights, including, but not limited to, loss of
      use, expenses involving costs of capital, loss of profits or revenues of
      the loss of use thereof, cost of purchased or replacement product
      (including additional expenses incurred in using existing manufacturing
      facilities).

      11.05 LICENSEE agrees to be responsible for and to defend, indemnify and
      save harmless CYGX from any and all claims, loss, damage or expense by
      reason of any accident, injuries, damages or injury to any person or
      property, including property of CYGX or LICENSEE, that may occur in
      connection with or related to the performance of this Agreement, and which
      is caused in whole or in part by the negligent act or omission of
      LICENSEE. This Paragraph 11.05 shall not include injuries or damage caused
      solely and directly by the negligent act or omission of CYGX. In the event
      injury or damage is caused by the joint negligence of CYGX and LICENSEE,
      each PARTY will share the

                                       12
<PAGE>
      loss arising from such injuries or damage in proportion with its
      percentage amount of negligence.

      11.06 LICENSEE shall indemnify and hold CYGX harmless from any and all
      fines, penalties, and costs (including cleanup costs and any damages to
      the environment) for any violations of any federal, state or local laws,
      regulations, rules and ordinances which result or arise from the
      evaluation, testing, analysis, transportation, storage, disposal or any
      other handling or use by LICENSEE or any subcontractor of LICENSEE of the
      sample of waste product supplied to LICENSEE by CYGX. LICENSEE agrees to
      defend any suit, enforcement action or cause of action brought against
      CYGX, its agents, servants or employees in connection with said violations
      or in order to collect said fines, penalties and costs and LICENSEE agrees
      to pay all fines, penalties, costs and expenses, including attorney's fees
      in connection therewith or resulting therefrom.

ARTICLE XII - PATENT MAINTENANCE

      12.01 It is understood that CYGX shall maintain any patent or patent
      application within Patents. Nonetheless, until CYGX notifies LICENSEE
      otherwise, CYGX is responsible for prosecuting those patent applications
      that are part of Patents and maintaining patents that result from such
      applications as well as those patents that are part of PATENTS. All costs
      associated with the maintenance of any PATENT and/or the prosecution of
      the PATENTS shall be incurred by CYGX.

      12.02 CYGX shall notify LICENSEE of any change in status of patents or
      patent applications within Patents. If CYGX elects not to continue
      prosecution of any patent application or to maintain any patent in
      Patents, CYGX shall promptly notify LICENSEE in writing and grant LICENSEE
      the right to continue patent prosecution or to maintain any such patent.
      All costs incurred by LICENSEE in continuing prosecution or in maintaining
      such patents shall be deducted from the royalty payments due to CYGX by
      LICENSEE under Article III hereof.

ARTICLE XIII - SUBLICENSES

      13.01 CYGX hereby grants to LICENSEE a non-exclusive power and right to
      extend to purchasers, mediate and immediate, of PRODUCT(s) sold by
      LICENSEE, immunity from suit for infringement of PATENTS arising out of
      such purchaser's use of such PRODUCT(s) in making compositions, or from
      the use or sale of the resulting compositions made with such PRODUCT(s),
      provided that such immunity extends only to said purchaser's practice
      using the PRODUCTS purchased from LICENSEE. Any limitations on using the
      subject matter of this Agreement in composing or preparing substances
      dispersed under this Agreement in the FIELD OF USE shall be imposed by
      mutual written consent of the PARTIES.

                                       13
<PAGE>
      13.02 Any sublicense and/or assignment of the CYGX Know-How license under
      Article II shall include a confidentiality provision no less favorable to
      CYGX than that of Article V above.

      13.03 In the event of termination of this Agreement pursuant to the
      provisions of this Article, no subsisting sublicense granted therefore by
      LICENSEE pursuant to this Agreement shall thereupon terminate, unless such
      effect is desired by the SUBLICENSEE, but shall instead become a direct
      license as between CYGX and the PARTY sublicensed.

      13.04 CYGX grants LICENSEE the right to sublicense the grant of Article II
      to agents and distributors of LICENSEE who are technically qualified in
      pharmaceutical compounding and dispensation of PHARMACOGENOMIC for the
      term of this Agreement for the purpose of selling Products to users of the
      same. CYGX reserves the right to define and limit the FIELD OF USE of such
      sublicenses. The terms of such sublicenses shall include the provisions of
      this Agreement shall terminate no later than termination of this Agreement
      under Article XXI. CYGX shall have the right to request LICENSEE to
      cancel, and LICENSEE shall cancel, such sublicenses provided CYGX can show
      that such agents or distributors are in breach of either of said
      provisions. A list of such agents and distributors is attached as Annex F.
      Additions to such list shall be made in writing by LICENSEE to CYGX.

      13.05 CYGX grants LICENSEE an exclusive right to sublicense others to
      make, use and sell under the claims of Patents.

      13.06 CYGX grants LICENSEE an exclusive right to sublicense KNOW-HOW to
      SUBLICENSEEs of Patents to make Products by the Process.

      13.07 The grant of Paragraph 2.01 above is subject to a right retained by
      CYGX and CYGX Affiliates to use CYGX Know-How and Confidential Information
      to practice the Process and Patents.

ARTICLE XIV - TAXES

      14.01 LICENSEE agrees to pay and bear the expense of local, state and/or
      federal government license, sales and use, property and ad valorem taxes
      which may be imposed or assessed on it with respect to payments made by
      LICENSEE to CYGX under this Agreement. To the extent any such taxes are
      imposed by non-U.S.A. governments and can be taken as a credit against
      CYGX's USA federal income taxes, LICENSEE will receive a credit in such
      amount against its liability hereunder.

      14.02 Payments under this Agreement are to be made directly from LICENSEE
      to CYGX and will not be subject to imposition of a foreign withholding
      tax. Any foreign withholding tax imposed on any payments to LICENSEE by a
      foreign SUBLICENSEE of LICENSEE shall be the responsibility of LICENSEE.

                                       14
<PAGE>
      14.03 All payments made hereunder shall be exclusive of all taxes due
      thereon except income taxes assessed against the payor by the government
      from which payment is made, in which event the payee shall submit a
      certificate to the payor relating to such deduction for use by the payor
      to receive possible credit therefor.

      14.04 Royalty payments hereunder shall be made without deduction for any
      taxes imposed by the United States Government or agency thereof except
      with respect to income tax charged to CYGX for which LICENSEE shall supply
      any necessary certificates in order that CYGX may obtain credit therefor.

ARTICLE XV - TECHNICAL ASSISTANCE

      15.01 CYGX will make available to LICENSEE Know-How regarding Processes,
      and instruct LICENSEE's representatives in procedures appropriate to the
      ProcessES. Process instruction manuals and any other written reports shall
      remain the sole property of CYGX and shall not be reproduced by LICENSEE
      without the express written approval of CYGX. Upon request, CYGX will
      furnish LICENSEE with the services of at least one technician qualified in
      Know-How, to the extent such person(s) are reasonably available in CYGX,
      to advise LICENSEE on utilization of Processes. Such personal services
      shall be made available during regular business hours at regular salary
      and credited to CYGX in-kind by LICENSEE.

ARTICLE XVI -  WAIVER

      16.01 Waiver of any one or more defaults or breaches under this Agreement
      shall not constitute a continuing waiver of the same or any other default
      or breach subsequently occurring.

      16.02 CYGX's waiver of its right to terminate this Agreement for any
      reason shall not be construed as a continuing waiver.

      16.03 The failure of either PARTY to insist in any one or more instances
      upon performance of any provisions of this Agreement shall not be
      construed as a waiver or relinquishment of any such provision, and the
      obligation of the other PARTY with respect to such future performance
      shall continue in full force and effect.

ARTICLE XVII - MOST FAVORED LICENSEE

      17.01 In the event CYGX hereafter grants to any third person a license
      covering the same or substantially the same matters as are covered by this
      Agreement at royalty rates more favorable to such third person than the
      royalty rates herein required of LICENSEE,

                                       15
<PAGE>
      the LICENSEE may, upon written request to CYGX, thereafter have the
      benefit of such more favorable royalty rates, provided LICENSEE also
      accepts the burden of any less favorable terms which may accompany such
      more favorable royalty rates.

      17.02 In the event CYGX shall at any time hereafter grant or amend
      licenses under Patents, Know-How or Confidential Information as licensed
      herein to a third PARTY to provide a royalty rate more favorable than
      those set forth herein, CYGX agrees to promptly so notify LICENSEE and
      LICENSEE may at its option, exercisable in writing within sixty (60) days
      after receipt of such notice, obtain such more favorable royalty rate for
      the applicable territory, effective as of the date of the grant to
      the-third PARTY, for so long as such royalty rate is available to such
      third PARTY provided, however, that LICENSEE shall also accept the burden
      of any less favorable terms which may accompany such more favorable
      royalty rate, and provided further, that CYGX may assign a fair value to
      patent rights on then existing inventions or to other considerations of
      real value received from said third PARTY in determining the royalty terms
      available to LICENSEE. For purposes of this Paragraph, affiliates and
      subsidiaries of CYGX shall not be construed as being third PARTIES.

ARTICLE XVIII - EXPORT CONTROLS

      18.01 Unless prior written authorization is obtained from the Office of
      Export Control, LICENSEE shall not export, directly or indirectly, any
      technical data which originated in the U.S.A., or the direct product of
      such technical data, in violation of Part 779 of the Export Control
      Regulations, as published by the United States Department of Commerce.
      This obligation shall survive any termination of this Agreement.

      18.02 LICENSEE further agrees to be bound by the terms of duly issued
      regulations and laws of the U.S.A. restricting or otherwise affecting the
      use by LICENSEE of CYGX's IP Rights and Confidential Information
      originating in the U.S.A., whether those regulations and laws are
      presently in effect or may become effective at any time during the term of
      this Agreement.

ARTICLE XIX - GOVERNMENT REGISTRATION

      19.01 It is understood that the license granted hereunder in some
      instances may be subject to registration and/or approval by local
      government authorities. The PARTY receiving the license shall be
      responsible for procuring any such registration and/or approval. The
      PARTIES agree to negotiate in good faith to amend this Agreement in order
      to accommodate, if possible, changes necessitated by the action of such
      authorities for such registration and/or approval.

      19.02 LICENSEE will, from time to time, when necessary or desirable under
      the laws of any country to which LICENSEE intends to export PRODUCT(s),
      execute such

                                       16
<PAGE>
      documents in generally approved form, and do such lawful acts as may be
      required to confirm, perfect, and register at LICENSEE's expense the
      licenses granted herein in respect of the material requiring registration.
      Specifically, LICENSEE will execute such documents and do such lawful acts
      as may be required to record at LICENSEE's expense the licenses granted
      herein before the appropriate government office requiring registry or at
      which registry may take place. LICENSEE shall notify CYGX at least Thirty
      (30) days of LICENSEE's intent to register material and the purpose for
      which registration is sought. Registration shall not be completed without
      written approval provided by CYGX. Such approval may not be unreasonably
      withheld.

      19.03 Upon termination or cancellation for any reason by either PARTY of
      the licenses granted herein, LICENSEE hereby empowers CYGX, or whomever
      CYGX may appoint, to take all necessary steps in the appropriate
      government agency to cancel any recordation of licenses granted herein and
      LICENSEE shall, at CYGX's request, do all such lawful acts as may be
      required to cancel any such recordation.

ARTICLE XX - NOTICES

      20.01 Any notices, reports and communications under this Agreement shall
      be in writing and sent via facsimile and confirmed in a document delivered
      by certified mail addressed as follows:

      If to CYGX:       Malcolm Skolnick
                        CytoGenix, Inc.
                        9881 South Wilcrest
                        Houston, TX 77099
                        (281) 988-6118
                        Facsimile: (281) 988-6727

      With a copy to:   Dell Gibson at CYGX

      If to LICENSEE:   L. David Sparks
                        9883 S. Wilcrest
                        Houston, TX 77099

      With a copy to:   Dean King at the LICENSEE's address

      Address for receipt of notice may be changed by either PARTY by giving the
      other PARTY at least thirty (30) days prior written notice of such change.

      20.02 The notices specified in Paragraph 20.01 shall be effective upon the
      first to occur

                                       17
<PAGE>
      of (a) receipt of a complete facsimile transmission of such notice and (b)
      the date when a registered or certified letter, duly addressed to the home
      office of the addressed PARTY, is deposited in the United States mails by
      the other PARTY. Until written notice of a change of address has been
      given, the addresses given in Paragraph 20.01 of this Agreement shall be
      considered the home office of the PARTIES.

ARTICLE XXI - TERMINATION

      21.01 Unless otherwise earlier terminated, this Agreement terminates upon
      expiration of the last Patent Rights to expire in the Territory or, if
      such initial term is extended for one or more additional terms by mutual
      agreement, upon expiration of such additional term(s).

      21.02 Following termination of this Agreement under Paragraph 20.01,
      LICENSEE will have the right to continue to use Know-How as provided in
      Article II.

      21.03 If either PARTY commits a material breach (including failure to make
      any royalty payment, during the immediately preceding calendar year, when
      due) of any provision of this Agreement and fails to correct such breach
      within SIXTY (60) days after written notice from the other PARTY, the
      non-breaching PARTY has the right to immediately terminate this Agreement
      without prejudice to any legal remedies available. Waiver by the
      non-breaching PARTY of its right to cancel this Agreement due to any
      particular breach of any provisions thereof shall not be construed as a
      continuing waiver.

      21.04 No termination of this Agreement shall affect obligations accrued
      prior to the date of termination, such as payment of royalties due on
      Products made or sold prior to such date in accordance with Article III
      above and LICENSEE's obligations of confidence under Article V above.

      21.05 The  rights  and  obligations  of  Articles  V-VII  shall  survive
      termination of this Agreement

      21.06 LICENSEE may terminate this Agreement at any time, by giving CYGX at
      least ninety (90) days prior written notice to such effect and returning
      to CYGX all written Know-How transmitted to LICENSEE by CYGX and/or copied
      or reduced to writing by LICENSEE. When the notice is given within one (1)
      year after the Effective Date, LICENSEE need not specify any reason for
      termination. Once that year has lapsed, LICENSEE must include a reason for
      termination in the notice and comply with all other provisions of this
      Article XXI. Notwithstanding such termination, all royalties that are due
      and payable must be paid, no monies shall be returned to LICENSEE and, as
      specified in Paragraph 21.05 above, the rights and obligations of Articles
      V-VII shall survive termination of this Agreement.

      21.07 If LICENSEE shall become bankrupt or insolvent and/or if the
      business of

                                       18
<PAGE>
      LICENSEE shall be placed in the hands of a Receiver, Assignee or Trustee,
      whether by the voluntary act of LICENSEE or otherwise, this Agreement
      shall immediately terminate.

      21.08 CYGX or LICENSEE, whoever is the aggrieved PARTY, may also terminate
      this Agreement by written notice to the other upon the occurrence of any
      one of the following events:

            (1) Failure of CYGX to transfer KNOW-HOW to LICENSEE pursuant to
      Paragraph 2.01 of this Agreement;
            (2) The term of payments are nullified or modified by any law,
      governmental decree, order or regulation;
            (3) Any of the material provisions of this Agreement are declared
      unenforceable by governmental authority;
            (4) The filing by either CYGX or LICENSEE of a voluntary petition in
      bankruptcy, an adjudication of bankruptcy, an assignment for the benefit
      of creditors, or the appointment of a receiver and the failure to vacate
      or supersede such appointment within THIRTY (30) days;
            (5) Sale of a membership interest of LICENSEE to any PARTY other
      than a member of LICENSEE or any wholly owned subsidiary thereof;
            (6) Failure of CYGX to enforce a patent contained in Patents;
            (7) LICENSEE's failure to exploit the licensed technology; or
            (8) A court determination that one or more licensed claims of
      Patents are invalid.

      21.10 If the holder of a Know-How license granted under Article II shall
      become bankrupt or insolvent and/or if the business of said holder shall
      be placed in the hands of a Receiver, Assignee for the Benefit of
      Creditors, or Trustee, whether by the voluntary act of said holder or
      otherwise, the Know-How license granted said holder, and any sublicense
      granted thereunder, shall immediately terminate.

      21.11 Termination of this Agreement under any paragraph of this Article
      XXI has no effect upon any of either PARTY's rights or remedies at law or
      in equity.

      21.12 Following termination of this Agreement, LICENSEE shall, provided it
      is not a breaching PARTY, have a limited right to sell off any remaining
      inventory of Products subject to payment of royalties as specified in
      Article III of this Agreement on such sales. The right shall be limited to
      a time period of One (1) year after termination becomes effective.

      21.13 In the event the PharmaGenix LLC operations are terminated and the
      PharmaGenix LLC is "wound-up" the property CYGX is licensing under this
      Agreement shall revert to CYGX.

ARTICLE XXII - FORCE MAJEURE

                                       19
<PAGE>
      22.01 If a FORCE MAJEURE circumstance occurs, the PARTY so affected shall
      be excused from the performance of the particular obligation affected
      during the period of the Force Majeure circumstance to the extent so
      hindered or prevented.

      22.02 If a FORCE MAJEURE circumstance continues for a period of Three (3)
      months, then either PARTY to this Agreement shall have the right to
      terminate this Agreement upon Sixty (60) days prior written notice to the
      other PARTY.

ARTICLE XXIII - GENERAL ASSURANCES

      23.01 The PARTIES agree to execute, acknowledge and deliver all such
      further instruments, and to do all such other acts as may be necessary or
      appropriate in order to carry out the intent and purposes of this
      Agreement.

ARTICLE XXIV - CURRENCY CONVERSION

      24.01 For converting into USA dollars a fee accrued in the currency of any
      country where PRODUCTS are sold, the conversion rate shall be the selling
      rate for USA dollars as certified by an authorized foreign exchange dealer
      in the country where that currency originates on the date of remittance
      or, in the case of late payment, the last business day of the quarter for
      which payment is being made. For a fee accrued in another currency, the
      fee shall be converted first to the currency from the country referred to
      in line 1 of this paragraph using the buying rate for the other currency
      and then converted to USA dollars as provided above.

ARTICLE XXV - ARBITRATION/MEDIATION

      25.01 Any controversy arising out of, or relating to, this contract or any
      modification or extension thereof, including any claim for damages or
      rescission, or both, may be settled by mediation or arbitration in
      Houston, Texas in accordance with the rules then in effect of the American
      Arbitration Association if Arbitration is the mutual choice of the
      PARTIES. If the PARTIES by mutual choice elect mediation, the mediator
      chosen to preside shall be mutually agreed upon and selected from a list
      compiled by the PARTIES.

      25.02 The PARTIES consent to the jurisdiction of the Supreme Court of the
      State of Texas, and of the United States District Court for the Southern
      District of Texas for all purposes in connection with arbitration. The
      PARTIES consent that any process or notice of motion or other application
      to either of said courts, and any paper in connection with arbitration,
      may be served by certified mail, return receipt requested or by personal
      service or in such other manner as may be permissible under the rules of
      the applicable

                                       20
<PAGE>
      court or arbitration tribunal, provided a reasonable time for appearance
      is allowed.

      25.03 Selection of the arbitrator(s) shall be in accordance with the rules
      specified in Paragraph 25.01 above; provided, however, that in all cases
      an odd number of arbitrators shall be chosen. The language of arbitration
      and of any decision or award shall be English.

      25.04 The award rendered by the arbitrator(s) shall be based upon a
      majority decision.

      25.05 The PARTIES further agree that arbitration or mediation proceedings
      must be instituted within one year after the claimed breach occurred. If
      the PARTIES cannot agree on a choice of mediation or arbitration within
      one year after the claimed breach occurred, resort to standard legal
      remedies may be pursued.

      25.06 The PARTIES still further agree that judgment upon the award
      rendered by the Arbitrator(s) shall be binding on the PARTIES and may be
      entered in either of the Courts specified in Paragraph 25.02 above.

ARTICLE XXVI - RELEASE FOR PAST INFRINGEMENT

      26.01 CYGX releases LICENSEE and all purchasers and users of Products
      acquired, directly or indirectly, from LICENSEE from all claims, demands,
      and rights of action that CYGX may have on account of any infringement or
      alleged infringement of any claim of Patents by the manufacture, use,
      lease, sale or other disposition of Products that, prior to the Effective
      Date, were manufactured, used, leased, sold or otherwise disposed of by
      LICENSEE.

ARTICLE XXVII - OTHER RIGHTS AND OBLIGATIONS

      27.01 ENTIRE AGREEMENT This Agreement constitutes the entire agreement
      between the PARTIES relating to the subject matter of this Agreement and
      supersedes all prior discussions between the PARTIES. There are no terms,
      obligations, covenants, express or implied warranties, representations,
      statements or conditions other than those set forth in this Agreement. No
      variation or modification of this Agreement or waiver of any of its terms
      or provisions shall be valid unless in writing and signed by both PARTIES.

      27.02 SEVERABILITY. Should any part of this Agreement for any reason be
      declared invalid or unenforceable, such decision shall not affect the
      validity or enforceability of any remaining portion, which remaining
      portion shall remain in force and effect as if this Agreement had been
      executed with the invalid or unenforceable portion thereof eliminated and
      it is hereby declared the intention of the PARTIES hereto that they would
      have executed the remaining portion of this Agreement without including
      therein any such part, parts or portion which may, for any reason, be
      hereafter declared invalid or

                                       21
<PAGE>
      unenforceable. Should any material term of this Agreement be in conflict
      any laws or regulations, the PARTIES shall in good faith attempt to
      negotiate a lawful modification of this Agreement which will preserve, to
      the greatest extent possible, the original expectation of the PARTIES.
      Should any provision of this Agreement be or become void because of being
      at variance with a law or decree of any pertinent governmental body, the
      remainder of this Agreement shall remain binding on both PARTIES. The
      PARTIES will use their best efforts to agree upon any changes in this
      Agreement which may be necessary in order to adjust its remaining
      provisions with regard to the omission of any invalid term in order to
      make this Agreement workable.

      27.03 COPYRIGHT OR TRADEMARK. No license under any copyright or trademark
      of CYGX is granted under this Agreement

      27.04 COMPLIANCE. LICENSEE will comply with any applicable laws and
      regulations, including, but not limited to, applicable local, regional or
      national safety and environmental legislation.

      27.05 CHOICE OF LAW. This Agreement is to be construed by and interpreted
      in accordance with the laws of the State of Texas, U.S.A., without regard
      to any conflict of law principles of Nevada, U.S.A. All questions
      concerning the construction or effect of patent applications and patents
      shall be decided in accordance with the laws of the country in which the
      particular patent application or patent concerned has been filed or
      granted, as the case may be.

      27.06 INDEPENDENT CONTRACTORS. In the performance of this Agreement, CYGX
      and LICENSEE are independent contractors. Neither PARTY nor any of its
      employees or agents shall be considered an employee or agent of the other
      PARTY. Nor shall any partnership, co-venture or joint-employer
      relationship be created or implied by virtue of this Agreement or of its
      performance. The PARTIES intend that this Agreement shall not create a
      partnership for tax purposes.

      27.07 ASSIGNMENT. This Agreement may not be assigned by LICENSEE.

      27.08 LANGUAGE. For all purposes, the English Language shall be used and
      prevail in all matters affecting this Agreement.

      27.09 NON-ASSERTION. CYGX agrees that it will not assert any patent rights
      that are now owned or later acquired against LICENSEE or any of LICENSEE's
      customers in any manner that limits the rights granted under Article II
      above.

                                       22
<PAGE>
IN WITNESS WHEREOF the PARTIES have caused this Agreement to be executed by
their duly authorized representatives as of the date first above written.

CYGX                                      LICENSEE

By:                                       By:
   ---------------------------------         -----------------------------------

Name: Malcolm H. Skolnick                 Name: L. David Sparks
Title: President and CEO                  Title: Vice-President,
                                                 PharmaGenix, Inc.

                                       23
<PAGE>
                                     ANNEX A

                                    KNOW HOW

      KNOW HOW shall include all non-patentable proprietary technology including
but not limited to know-how, show-how, trademark, trade dress, copyright, trade
secret, confidential information, and/or proprietary information that is/are
owned and/or developed by CYGX developed and/or held by CYGX as may be
applicable to commercialization opportunities in the FIELD OF USE, or to which
CYGX has license right. Such KNOW HOW may consist of any formula, pattern,
device, or compilation of information which is used in CYGX's business, and
which gives CYGX an opportunity to obtain an advantage over competitors who do
not know or use it. It may be a formula for a chemical compound, a process of
manufacturing, treating or preserving materials, a pattern for a machine or
other device, or a list of customers. Furthermore, it may be a process or device
for continuous use in the operation of the business.

                                       24
<PAGE>
                                     ANNEX B

                       Patents and Patent Applications
                [File history to be updated from time to time]

1.    U.S. Patent Application -- Serial No. 08/236,504 (filed April 29, 1994) --
      entitled "Stem-Loop Cloning Method and Vector"
2.    U.S. Patent Application -- Serial No. 08/877,251 (filed June 17, 1997) --
      entitled "Stem-Loop Cloning Method and Vector" -- Notice of Allowance
      December 28, 1998
3.    U.S. Patent Application -- Serial No. 09/169,793 (filed October 9, 1998)
      -- entitled "Stem-Loop Cloning Method and Vector"
4.    U.S. Patent Application -- Serial No. 09/397,782 (filed September 16,
      1999) -- entitled "In Vivo Production of ssDNA Using Reverse Transcriptase
      with Predefined Reaction Termination via Step-Loop Formation"
5.    U.S. Patent Application -- Serial No. 09/397,783 (filed September 16,
      1999) -- entitled "Enzymatic Synthesis of ssDNA"
6.    U.S. Patent Application -- Serial No. 09/411,568 (filed October 4, 1999)
      -- entitled "In Vivo Production of ssDNA Containing DNA Enzyme Sequence
      with Rnase Activity"
7.    International Application -- No. PCT/US99/23936 (filed October 12, 1999 --
      entitled "Production of ssDNA In Vivo"
8.    International Application -- No. PCT/US99/23933 (filed October 12, 1999)
      -- entitled "Enzymatic Synthesis of ssDNA"

                                       25EXHIBIT 10.4

TECHNOLOGY TRANSFER AGREEMENT

THIS AGREEMENT is made by and between InGene,lnc. (INGENE), a Kansas corporation
having an address at 8496 West 116th Street, Overland Park, Kansas 66210 and
Cryogenic Solutions, Inc. (CYGS), a Nevada corporation having a principal place
of business located at 6524 San Felipe, Suite 388, Houston, Texas 77057.

WITNESSETH:

Whereas INGENE and CYGS have executed a license effective on May l, 1997 for
patent and technology rights (LICENSE I) which is attached and hereby
incorporated for reference herein; and

Whereas INGENE owns individually and jointly certain PATENT RIGHTS and
TECHNOLOGY RIGHTS comprising LICENSED SUBJECT MATTER in addition to the patent
and technology rights licensed in LICENSE I; and

Whereas INGENE desires to have the LICENSED SUBJECT MATTER developed and used
for the benefit of CYGS, INGENE and the public; and

Whereas CYGS wishes to obtain a license and to practice the LICENSED SUBJECT
MATTER.

NOW, THEREFORE, in consideration of the mutual covenants and premises herein
contained, the parties hereto agree as follows:

I. EFFECTIVE DATE

This Agreement shall be effective as of June 26, 1998.

II. DEFINITIONS

As used in this Agreement, the following terms shall have the meanings
indicated:

     2.1 LICENSED FIELD shall mean use of compositions and methods using
     stem-loop vector technology to produce short, single stranded
     Deoxyribonucleic Acid (ssDNA) of desired sequence specifications for
     anti-sense, triplex formation, and ribozyme production and delivery
     applications thereof.
<PAGE>
     2.2 LICENSED PRODUCT shall mean any product SOLD by CYGS which is covered
     by the license granted to CYGS under this Agreement.

     2.3 LICENSED SUBJECT MATTER shall mean, TECHNOLOGY RIGHTS, and PATENT
     RIGHTS as defined hereinbelow.

     2.4 LICENSED TERRITORY shall mean the world.

     2.5 NET SUB-LICENSING INCOME shall mean the gross amount received by CYGS
     or its Affiliates from sub-licensing TECHNOLOGY RIGHTS or PATENT RIGHTS
     granted by this Agreement less federal, or state taxes, bank transfer or
     currency conversion fees associated with payment by sub-licensee(s) to CYGS
     pursuant to valid and executed sub-licenses or other expenses born by CYGS
     incident to transfer of payment or funds from sub-licensee(s) to CYGS for
     sub-license of PATENT and/or TECHNOLOGY RIGHTS.

     2.6 NET SALES shall mean the gross amount invoiced by CYGS or its
     Affiliates from the SALE of LICENSED PRODUCTS less sales, use and/or excise
     tax actually paid, import and/or export duties actually paid, outbound
     transportation prepaid or allowed, trade and or quantity discounts, cash
     discounts allowed and amounts allowed or credited due to returns (not to
     exceed the original billing or invoice amount).

     2.7 PATENT RIGHTS shall mean INGENE's rights in information or discoveries
     covered at any time by patents and/or patent applications, whether domestic
     or foreign, and all divisions, continuations, and any letters patent that
     issue thereon, which name CONRAD as inventor and do not name any officer,
     employee consultant (other than CONRAD) or agent of CYGS and which relate
     to the manufacture, use or sale of products derived from uses of Stem-Loop
     Cloning Vectors and methods for using same including but not limited to the
     use of Stem-Loop Vector to produce short, single stranded Deoxyribonucleic
     Acid (ssDNA) of desired sequence specification including but not limited to
     a specific patent application titled, and the subject of U.S. Serial No.
     08/236,504 filed April 29, 1994, titled STEM-LOOP CLONING VECTOR AND
     METHOD. PATENT RIGHTS shall also include all of INGENE's rights in
     information or discoveries covered by patents and/or patent applications,
     whether domestic or foreign, and all divisions, continuations,
     continuations-in-part, reissues, reexaminations or extensions thereof, and
     any letters patent that issue thereon, which relate to the invention,
     design, manufacture, use or SALE of any LICENSED PRODUCTS sponsored by CYGS
     pursuant to the Sponsored Research Agreement executed concurrently
     herewith.
<PAGE>
     2.8 SALE or SOLD shall mean the transfer or disposition of a LICENSED
     PRODUCT or product made using technology assigned under this Agreement for
     value to a party other than CYGS or a SUBSIDIARY.

     2.9 SUBSIDIARY shall mean any business entity more than 50% owned by CYGS,
     any business entity which owns more than 50% of CYGS, or any business
     entity that is more than 50% owned by a business entity that owns more than
     50% of CYGS.

     2.10 TECHNOLOGY RIGHTS shall mean INGENE's rights in any technical
     information, know-how, process, procedure, composition, device, method,
     formula, protocol, technique, software, design, drawing or data relating to
     Stem-Loop Cloning Vectors and methods for using same including but not
     limited to the use of p-ANTI-T vector to produce short, single stranded
     Deoxyribonucleic Acid (ssDNA) of desired sequence specification and use of
     ssDNA in anti-sense, triplex formation, and ribozyme production and
     delivery applications which are not covered by PATENT RIGHTS but which are
     necessary for practicing the invention at any time covered by PATENT RIGHTS
     and/or which are necessary to develop materials, devices and/or processes
     in the FIELD OF USE.

III. WARRANTY: SUPERIOR-RIGHTS

     3.1 INGENE represents and warrants that it is the owner of the entire
     right, title, and interest in and to LICENSED SUBJECT MATTER, and that
     INGENE has the sole right to grant licenses thereunder, and that it has not
     granted licenses thereunder to any other entity that would restrict rights
     granted hereunder except as stated herein.

IV. LICENSE

     4.1 INGENE hereby grants to CYGS an exclusive, world-wide, royalty-bearing
     license under LICENSED SUBJECT MATTER to manufacture, have manufactured,
     and/or sell LICENSED PRODUCTS for use within LICENSED FIELD. This grant
     shall be subject to the payment by CYGS to INGENE of all consideration as
     provided in this Agreement, and shall be further subject to rights retained
     by INGENE to:
<PAGE>
          (a) Publish the general scientific finding from research related to
          LICENSED SUBJECT MATTER; however, in order to avoid loss of
          intellectual property rights as a result of public disclosure of
          patentable or proprietary information, INGENE will submit any material
          to CYGS for review at least ninety (90) days prior to planned
          submission. CYGS will notify INGENE within thirty (30) days of receipt
          of such materials: (1) whether it desires INGENE to file patent
          applications on any inventions contained in the materials or (2)
          whether such materials contain information whose publication would be
          commercially prejudicial to CYGS. CYGS shall have the right to request
          that any commercially prejudicial information be deleted from the
          materials or that indicated portions of the materials be rewritten to
          be less prejudicial; provided, however, that faculty author(s) of the
          material shall have the final authority to determine the scope and
          content of any publication; and

          (b) Use any information contained in LICENSED SUBJECT MATTER for
          research, teaching and other educationally-related purposes which is
          not prejudicial to the commercial interests of CYGS.

     4.2 CYGS shall have the right to extend the license granted herein to any
     SUBSIDIARY provided that such SUBSIDIARY consents to be bound by this
     Agreement to the same extent as CYGS.

     4.3 CYGS shall have the right to grant sub-licenses consistent with this
     Agreement provided that CYGS shall be responsible for the operations of
     each sub-CYGS relevant to this Agreement as if such operations were carried
     out by CYGS, including the payment of royalties, if any, whether or not
     paid to CYGS by the sub-CYGS. CYGS further agrees to deliver to INGENE a
     true and correct copy of each sub-license granted by CYGS, and any
     modification or termination thereof, within thirty (30) days after
     execution, modification, or termination

V. CONSIDERATION AND REPORTS

     5.1 In consideration for an exclusive, world-wide license to develop,
     promote commercialize and sub-license TECHNOLOGY in the LICENSED FIELD,
     CYGS agrees to:

          (a) Transfer Two Hundred Thousand (200,000) CYGS unrestricted shares
          to INGENE;

          (b) Transfer Three Hundred Thousand (300,000) CYGS restricted shares
          to INGENE;
<PAGE>
          (c) Provide INGENE options to purchase up to Three Hundred Thousand
          (300,000) CYGS restricted Shares at Par Value ($.001 )

          (d) Provide INGENE options to purchase up to Three Hundred Thousand
          (300,000) CYGS restricted Shares at Ten percent (10%) of Market Value
          of said shares on the date indicated on INGENE's notarized notice of
          exercising this option as received by CYGS;

          (e) Provide INGENE options, on the second and third year anniversaries
          of the EFFECTIVE DATE of the License Agreement, to purchase CYGS
          restricted Shares in the amount necessary to bring INGENE's Share
          holdings to a total equivalent to four and one-half percent of issued
          Shares at a price of Ten percent (10%) of market value on the date
          indicated on INGENE's notarized notice of exercising this option as
          received by CYGS;

          (f) Pay INGENE a royalty of Eight percent (8%) of NET SALES of
          LICENSED PRODUCTS and/or NET SUBLICENSING INCOME to CYGS.

          (g) Purchase patent insurance for all issued patents subject of the
          License Agreements;

          (h) provide INGENE quarterly reports of sub-licensing and Sub-Licensee
          activity; level of detail of said reports to be determined; and

          (i) Renew and continue the Sponsored Research Agreement now in force
          between CYGS and INGENE at a level appropriate to continue necessary
          and mutually agreed upon research.

     5.2 During the Term of this Agreement and for one (1) year thereafter, CYGS
     shall keep complete and accurate records of its and its sub-licensees
     SALES, NET SALES of LICENSED PRODUCTS and NET SUB-LICENSING INCOME under
     the license granted in this Agreement in sufficient detail to enable the
     royalties payable hereunder to be determined. CYGS shall permit INGENE or
     its representatives, at INGENE'S expense, to periodically examine its
     books, ledgers, and records during regular business hours for the purpose
     of and to the extent necessary to verify any report required under this
     Agreement. In the event that the amounts due to INGENE are determined to
     have been underpaid, CYGS shall pay the cost of such examination, and
     accrued interest at the highest allowable rate on the amounts underpaid.
<PAGE>
     5.3 Within sixty (60) days after March 31, June 30, September 30 and
     December 31 CYGS shall deliver to INGENE a true and accurate report,
     giving such particulars of the business conducted by CYGS and its
     sub-licensees, if any exist, during the preceding three (3) calendar months
     under this Agreement as are pertinent to an account for payments hereunder.
     Such report shall include at least (a) the quantities of LICENSED SUBJECT
     MATTER that it has produced; (b) the total SALES, the calculation of
     royalties thereon and (d) the total royalties so computed and due INGENE.
     Simultaneously with the delivery of each such report, CYGS shall pay to the
     INGENE the amount, if any, due for the period of such report. If no
     payments are due, it shall be so reported.

     5.4 Upon the request of INGENE but not more often than once per calendar
     year, CYGS shall deliver to INGENE a written report as to CYGS'S efforts
     and accomplishments during the preceding year in commercializing LICENSED
     SUBJECT MATTER and its commercialization plans for the upcoming year.

     5.5 All amounts payable hereunder by CYGS shall be payable in United States
     funds. Checks shall be made payable to INGENE and sent to INGENE.

     5.6 With the right of prior approval, CYGS shall reimburse INGENE for all
     future expenses incurred by INGENE in searching, preparing, filing,
     prosecuting and maintaining patent applications and patents including any
     reissue and/or re-examination, relating to PATENT RIGHTS so long as and in
     such countries as its license remains exclusive.

VI. TERM AND TERMINATION

     6.1 The Term of this Agreement shall extend from the Effective Date set
     forth hereinabove to the full end of the term or terms for which PATENT
     RIGHTS have not expired and if only TECHNOLOGY RIGHTS are licensed and no
     PATENT RIGHTS are applicable, for a term of fifteen (15) years.

     6.2 This Agreement will earlier terminate:

          (a) automatically if CYGS shall become bankrupt or insolvent and/or if
          the business of CYGS shall be placed in the hands of a receiver or
          trustee, whether by voluntary act of CYGS or otherwise; and the
          receiver or trustee does not elect to accept this agreement with
          approval of an appropriate court or by law.

          (b) upon ninety (90) days written notice if CYGS shall breach or
          default on any obligation under this License Agreement; provided,
          however, CYGS may avoid such termination if before the end of such
          period CYGS notifies INGENE that such breach has been cured and states
          the manner of such cure.
<PAGE>
     6.3 Upon termination of this Agreement for any cause, nothing herein shall
     be construed to release either party of any obligation matured prior to the
     effective date of such termination, CYGS may, after the effective date of
     such termination, sell all LICENSED PRODUCT and parts therefore that it may
     have on hand at the date of termination, provided that it pays earned
     royalty thereon as provided in this Agreement.

VII. INFRINGEMENT BY THIRD PARTIES

     7.1 CYGS shall have the obligation of enforcing at its expense any patent
     exclusively licensed hereunder against infringement by third parties and
     shall be entitled to retain recovery from such enforcement. After payment
     of its direct legal expenses, CYGS shall pay INGENE royalty on any monetary
     recovery according to the provisions of Paragraph 5.1(b) to the extent that
     such monetary recovery by CYGS is held to be reasonable damages or a
     royalty in lieu thereof. In the event that CYGS does not file suit against
     or grants a sub-license to a substantial infringer of such patents within
     six (6) months of knowledge thereof, then INGENE shall have the right to
     enforce any patent licensed hereunder on behalf of itself and CYGS with
     INGENE retaining all recoveries from such enforcement and/or reduce the
     license granted hereunder to non-exclusive.

     7.2 In any suit or dispute involving an infringer, the parties shall
     cooperate fully, and upon the request and at the expense of the party
     bringing suit, the other party shall make available to the party bringing
     suit at reasonable times and under appropriate conditions all relevant
     personnel, records, papers, information, samples, specimens, and the like
     which are in its possession.

VIII. ASSIGNMENT

The license conveyed by this Agreement may not be assigned by CYGS without the
prior written consent of INGENE.

IX. PATENT MARKING

CYGS agrees to mark permanently and legibly all products and documentation
manufactured or sold by it under this Agreement with such patent notice as may
be permitted or required under Title 35, United States Code.

<PAGE>
X. INDEMNIFICATION

CYGS shall hold harmless and indemnify INGENE, its officers, employees and
agents from and against any claims, demands, or causes of action whatsoever,
including without limitation those arising on account of any injury or death of
persons or damage to property caused by, or arising out of, or resulting from,
the exercise or practice of the license granted hereunder by CYGS or its
officers, employees, agents or representatives.

XI. USE OF INGENE's OR CYGS' NAME

Neither party shall use the name of the other without express written consent.

XII. CONFIDENTIAL INFORMATION

     12.1 INGENE and CYGS each agree that all information contained in documents
     marked "confidential" which are forwarded to one by the other shall be
     received in strict confidence, used only for the purposes of this
     Agreement, and not disclosed by the recipient party (except as required by
     law or court order), its agents or employees without the prior written
     consent of the other party, unless such information (a) was in the public
     domain at the time of disclosure; (b) later became part of the public
     domain through no act or omission of the recipient party, its employees,
     agents, successors or assigns; (c) was lawfully disclosed to the recipient
     party by a third party having the right to disclose it; (d) was already
     known by the recipient party at the time of disclosure; (e) was
     independently developed; or (f) is required to be submitted to a government
     agency pursuant to any pre-existing obligation.

     12.2 Each party's obligation of confidence hereunder shall be fulfilled by
     using at least the same degree of care with the other party's confidential
     information it uses to protect its own confidential information. This
     obligation shall exist while this agreement is in force and for a period of
     five (5) years thereafter.

XIII. GENERAL

     13.1 This Agreement and the existing License between the parties
     (appended) constitute the entire and only agreement between the parties for
     LICENSED SUBJECT MATTER and all other prior negotiations, representations,
     agreement, and understandings are superseded hereby. No agreements altering
     or supplementing the terms hereof may be made except by means of a written
     document signed by the duly authorized representatives of the parties.
<PAGE>
     13.2 Any notice required by this License Agreement shall be given by
     prepaid, first class, certified mail, return receipt requested, addressed
     in the case of INGENE to:

     Charles Conrad, MD, President
     InGene, Inc.
     8496 West 116th Street
     Overland Park, Kansas 66210

     or in the case of CYGS to:

     Michael Skillern, President
     Cryogenic Solutions, Inc.
     6524 San Felipe, Suite 388,
     Houston, Texas 77057.

     or such other addresses as may be given from time to time under the terms
     of this notice provision.

     13.3 CYGS and INGENE shall comply with all applicable federal, state and
     local laws and regulations in connection with the activities pursuant to
     this Agreement.

     13.4 This License Agreement shall be construed and enforced in accordance
     with the laws of the State of Texas.

     13.5 Failure of INGENE or CYGS to enforce a right under this Agreement
     shall not act as a waiver of that right or the ability to later assert that
     right relative to the particular situation involved.

     13.6 Headings included herein are for convenience only and shall not be
     used to construe this Agreement.

     13.7 If any provision of this Agreement shall be found by a court to be
     void, invalid or unenforceable, the same shall be reformed to comply with
     applicable law or stricken if not so conformable, so as not to affect the
     validity or enforceability of this Agreement.

IN WITNESS WHEREOF, parties hereto have caused their duly authorized
representatives to execute this AGREEMENT.

INGENE (Charles Conrad, MD)                     CYGS (Michael Skillern)
By CHARLES CONRAD                               By MICHAEL SKILLERN
    President                                       President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]